News

Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40 Percent
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
Medscape2h
FDA Widens Indication of Finerenone for Heart Failure Patients
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
FDA approves Kerendia for heart failure with ejection fraction of 40% or higher
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Clinical Advisor7h
Kerendia Approved for Patients With Heart Failure and LVEF ≥40%
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
MedPage Today on MSN2d
Finerenone Gets Expanded FDA Approval in Heart Failure
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
InvestorsHub on MSN7h
Tempus AI shares climb after FDA approval of heart monitoring software
Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...
PharmExec2d
FDA Approves Bayer’s Kerendia for Heart Failure with Preserved Ejection Fraction to Reduce Cardiovascular Death and Hospitalization Risk
Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...
pharmaphorum2d
Bayer gets sought-after heart failure use for Kerendia
The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...
Fierce Pharma2d
Bayer's Kerendia wins FDA label expansion to treat 2 types of heart failure
The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...
TMCnet8h
Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now ...
The Cardiology Advisor5h
Unintentional Weight Loss in HFpEF May Indicate Poor Prognosis
Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.
AHA/ASA Journals1d
The Promise and Peril of Learning Algorithms and Predictive Models in Clinical Decision Support: Be Careful What You Train For
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...